HomeComparePFE vs SYK

PFE vs SYK: Dividend Comparison 2026

PFE yields 6.20% · SYK yields 1.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $7.8K in total portfolio value· pulled ahead in Year 10
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
SYK
SYK
● Live price
1.04%
Share price
$326.10
Annual div
$3.40
5Y div CAGR
46.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.3K
Annual income
$8,282.98
Full SYK calculator →

Portfolio growth — PFE vs SYK

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFESYK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + SYK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
SYK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
SYK
Annual income on $10K today (after 15% tax)
$88.62/yr
After 10yr DRIP, annual income (after tax)
$7,040.53/yr
At 15% tax rate, PFE beats the other by $16,088.43/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + SYK for your $10,000?

PFE: 50%SYK: 50%
100% SYK50/50100% PFE
Portfolio after 10yr
$47.2K
Annual income
$17,746.76/yr
Blended yield
37.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYK right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
SYK
Analyst Ratings
1
Strong
35
Buy
14
Hold
Consensus: Buy
Price Target
$428.67
+31.5% upside vs current
Range: $390.00 — $469.00
Altman Z
4.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
SYK buys
0
No recent congressional trades found for PFE or SYK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFESYK
Forward yield6.20%1.04%
Annual dividend / share$1.72$3.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%46.2%
Portfolio after 10y$51.1K$43.3K
Annual income after 10y$27,210.54$8,282.98
Total dividends collected$60.1K$21.0K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusHoldBuy
Analyst price target$27.50$428.67

Year-by-year: PFE vs SYK ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrSYK PortfolioSYK Income/yrGap
1$9,161$701.38$10,852$152.43$1.7KSYK
2$8,610$859.79$11,838$226.03$3.2KSYK
3$8,366$1,081.25$13,004$336.89$4.6KSYK
4$8,483$1,405.66$14,420$505.63$5.9KSYK
5$9,084$1,907.24$16,195$766.09$7.1KSYK
6$10,418$2,732.78$18,504$1,175.64$8.1KSYK
7$13,007$4,193.56$21,635$1,835.40$8.6KSYK
8$18,010$7,005.87$26,082$2,932.10$8.1KSYK
9$28,216$12,979.89$32,737$4,829.68$4.5KSYK
10← crossover$51,081$27,210.54$43,312$8,282.98+$7.8KPFE

PFE vs SYK: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

SYKHealthcare

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Full SYK Calculator →
📬

Get this PFE vs SYK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.